One-Carbon Metabolism: Folate, B12 & SAMe

This document treats three supplements that the marketplace sells separately but that biochemistry refuses to separate: folate (and its active form L-methylfolate), vitamin B12 (cobalamin), and S-adenosylmethionine (SAMe). All three are nodes in a single biochemical circuit — the one-carbon (methylation) cycle — and their psychiatric effects, deficiencies, and hazards only make sense when the cycle is viewed whole.

The cycle's job is to move one-carbon units (methyl groups) around the cell. Dietary folate is reduced to 5-methyltetrahydrofolate (5-MTHF, L-methylfolate), the only folate species that crosses the blood–brain barrier and the form that donates a methyl group to homocysteine. That reaction — catalyzed by methionine synthase using vitamin B12 as cofactor — regenerates methionine, which is then activated to SAMe, the universal methyl donor for hundreds of reactions including neurotransmitter and phospholipid synthesis. Spend a methyl group and SAMe becomes SAH and then homocysteine, which is either re-methylated (closing the loop, requiring folate and B12) or shunted to cysteine. Folate, B12, and SAMe are thus three handholds on the same loop, and a deficiency anywhere raises homocysteine and lowers SAMe.

Proposed Mechanism

The cycle connects to mood through at least three routes.

Monoamine synthesis via tetrahydrobiopterin. L-methylfolate is required for the regeneration of BH4 (tetrahydrobiopterin), the obligatory cofactor for tyrosine hydroxylase and tryptophan hydroxylase — the rate-limiting enzymes of dopamine, norepinephrine, and serotonin synthesis. Inadequate central folate throttles monoamine production at its source.

Methylation capacity (the SAMe route). SAMe methylates phospholipids (membrane fluidity), DNA and histones (epigenetic regulation), and catecholamines. A depleted methylation pool plausibly degrades all of these simultaneously.

Homocysteine as marker and mediator. Elevated homocysteine — the cardinal biochemical signature of a stalled cycle — is associated with depression, vascular disease, and cognitive decline, and is itself neurotoxic and pro-oxidant. Whether homocysteine is a cause or merely a readout of the deficiency is unsettled, but it usefully links this cycle to cerebrovascular disease and vascular depression.

The MTHFR wrinkle. The common C677T polymorphism of methylenetetrahydrofolate reductase reduces the enzyme's efficiency, lowering 5-MTHF production. The TT genotype is modestly associated with depression risk (more clearly in some Asian populations). This is the genetic hook on which the entire L-methylfolate product category hangs — and, as below, it is also where the marketing outruns the data.

Evidence Base

Folate / L-methylfolate

The pivotal trials are Papakostas and colleagues' two parallel-sequential RCTs of adjunctive L-methylfolate 15 mg/day in SSRI-resistant MDD: the 15 mg dose separated from placebo; the 7.5 mg dose did not, establishing both a signal and a dose threshold. The 2022 meta-analysis (Maruf et al.) pooled the controlled evidence to a standardized mean difference of roughly −0.49 for the 15 mg dose — a respectable adjunctive effect, but derived from a modest number of patients, which the authors flagged. The British Association for Psychopharmacology position is the sensible distillation: do not use L-methylfolate as monotherapy; consider 15 mg as an SSRI adjunct.

The more interesting finding is who responds. Post-hoc analyses of the Papakostas trials located the benefit not primarily in MTHFR-genotype-positive patients but in those with elevated BMI and elevated inflammatory biomarkers — and benefit also tracked with MTR/MTRR polymorphisms, not MTHFR alone. The clean "test MTHFR, prescribe methylfolate" narrative that drives direct-to-consumer genetic testing is therefore not what the data actually show: the better-characterized L-methylfolate responder is the inflamed, metabolically burdened patient, re-routing this agent toward the same inflammatory-depression phenotype that recurs throughout this series.

SAMe

SAMe has a longer and more equivocal record. The strongest positive trial is Papakostas and colleagues (2010): SAMe 800 mg twice daily augmenting SRI non-responders beat placebo. Older monotherapy trials and a 1994 meta-analysis found SAMe roughly comparable to tricyclics with fewer side effects, and a 2024 meta-analysis concluded with moderate certainty that SAMe monotherapy offers a moderate benefit. But the counter-evidence is substantial: the 2016 Cochrane review (Galizia et al.) found no significant difference for SAMe versus placebo or antidepressants in monotherapy; Sarris and colleagues' 2018 adjunctive RCT in non-remittent MDD was negative; and the Mischoulon escitalopram-comparator trial was equivocal (a clinically suggestive but statistically non-significant MADRS reduction). Guidelines (CANMAT; WFSBP/CANMAT nutraceutical taskforce) advise against SAMe monotherapy but cautiously endorse 1,600–3,200 mg/day as an adjunct for mild-to-moderate MDD.

B12

B12's role is mostly permissive and corrective rather than independently therapeutic. Frank B12 deficiency produces a neuropsychiatric syndrome that can include depression, apathy, and cognitive impairment, and correcting it resolves those symptoms — but supplementing B12 in replete patients has not been shown to treat depression. B12 matters here primarily because it is the cofactor that makes folate usable and because of the masking hazard described below.

The honest synthesis: this cluster offers a genuine adjunctive effect (best evidenced for L-methylfolate 15 mg and SAMe ~1,600–3,200 mg added to an antidepressant), modest in size, strongest in deficiency or inflammation, and not a monotherapy substitute for standard care. Correcting documented deficiency is unambiguously worthwhile; supplementing the replete is where the evidence thins.

Who Might Benefit / Indications

The clearest indication is measured deficiency: low or low-normal folate or B12 (or elevated homocysteine) in a depressed patient warrants repletion as a matter of basic medicine, independent of any antidepressant effect. Beyond that, L-methylfolate 15 mg is a reasonable SSRI/SNRI adjunct in partial responders, with the best a priori case in patients who are overweight/obese or show inflammatory markers. SAMe is an option for adjunctive use in unipolar mild-to-moderate depression in patients who can tolerate an activating agent and who are reliably not bipolar. Routine MTHFR genotyping to guide prescribing is not supported as a stand-alone decision rule.

Formulation, Dosing & Bioavailability

• L-methylfolate: 15 mg/day is the evidence-based adjunctive dose (prescription "medical food" formulations exist; equivalent active 5-MTHF is available OTC). The active form bypasses the MTHFR conversion step, which is the rationale for preferring it over folic acid in this context.
• Folic acid caution: high-dose unmetabolized folic acid (the synthetic form) is a distinct entity from 5-MTHF and carries its own concerns (immune effects, possible promotion of certain neoplasms); the active form is preferable for psychiatric use.
• SAMe: start low and titrate (e.g., 200–400 mg/day up to 800–1,600 mg, occasionally 3,200 mg), taken on an empty stomach, morning/midday to avoid insomnia. Use enteric-coated, stabilized salts (tosylate or butanedisulfonate); SAMe is chemically unstable and expensive, and product quality varies widely.
• B12: repletion dosing depends on cause (oral high-dose vs parenteral for malabsorption/pernicious anemia).

Always check and correct B12 before or alongside folate, because folate can partially correct the anemia of B12 deficiency while the neurological damage progresses unchecked — the classic masking problem.

Safety & Interactions

Three hazards deserve emphasis:

1. SAMe and the manic switch. SAMe is the most activating agent in this series and can precipitate hypomania or mania. The risk is real enough that SAMe is generally contraindicated in bipolar disorder; older open data reported switch in a majority of bipolar patients exposed. Screen for bipolarity before recommending it, and counsel patients to stop and report activation, racing thoughts, or sleeplessness.
2. Serotonergic additivity. Because SAMe and active folate can augment serotonergic tone, combining them with serotonergic antidepressants carries a (small, largely theoretical) serotonin-toxicity consideration; relevant mainly with multiple serotonergic agents.
3. B12 masking (above), and SAMe's capacity to methylate levodopa, potentially reducing its efficacy in Parkinson disease.

Otherwise, L-methylfolate and B12 are very well tolerated. SAMe's common nuisance effects are GI upset, insomnia, anxiety, sweating, and dry mouth.

Convergence

This cycle is a hub. Its BH4 dependence ties it to monoaminergic dysfunction; its methylation output to genetics and epigenetics; its homocysteine readout to cerebrovascular disease. The L-methylfolate responder phenotype routes back to inflammation and metabolic burden, echoing the targeting logic of omega-3. Within this series it shares the "correct the deficiency, don't oversell the supplement" lesson with vitamin D and magnesium and zinc.

Caveats

The one-carbon story is a magnet for two opposite errors. The first is therapeutic nihilism — dismissing folate and B12 because the trials are modest, when uncorrected deficiency is a genuine and reversible contributor to low mood that every clinician should screen for. The second is mechanistic overreach — the MTHFR-testing industry, which markets a clean genotype-to-prescription pipeline that the trial data do not support, and which can pathologize an extremely common, often clinically inert polymorphism. Hold both lines: correct documented deficiency diligently; deploy L-methylfolate and SAMe as honest, modest adjuncts; and resist genotype-driven prescribing dressed up as precision medicine.

Bottom Line

Folate, B12, and SAMe are three handholds on one methylation loop. Screen for and correct deficiency (low folate/B12, high homocysteine) as standard care. L-methylfolate 15 mg/day is a reasonable SSRI adjunct in partial responders — best where BMI and inflammation are elevated, not merely where MTHFR is positive. SAMe (1,600–3,200 mg/day) is a defensible adjunct in unipolar mild-to-moderate depression but is activating and contraindicated in bipolar disorder. The effects are modest, the deficiency-correction rationale is solid, and MTHFR genotyping is not a stand-alone prescribing rule.

Key References

1. Papakostas GI, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012.
2. Maruf AA, et al. L-methylfolate augmentation in depressive disorders: systematic review and meta-analysis. Pharmacopsychiatry. 2022.
3. Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry. 2009.
4. Papakostas GI, et al. S-adenosyl-methionine (SAMe) augmentation of SRIs for non-responders with MDD: a double-blind RCT. Am J Psychiatry. 2010.
5. Galizia I, Oldani L, Macritchie K, et al. S-adenosyl methionine (SAMe) for depression in adults. Cochrane Database Syst Rev. 2016.
6. Sarris J, et al. Adjunctive SAMe in treating non-remittent MDD: an 8-week double-blind RCT. Eur Neuropsychopharmacol. 2018.
7. Sarris J, et al. SAMe monotherapy for depression: an 8-week double-blind RCT. Psychopharmacology (Berl). 2020.
8. Mischoulon D, et al. SAMe vs escitalopram vs placebo in MDD. J Clin Psychiatry. 2014.
9. Sharma A, et al. SAMe for neuropsychiatric disorders: a clinician-oriented review. J Clin Psychiatry. 2017.
10. Peng TR, et al. SAMe as adjuvant therapy for depression: an updated systematic review and meta-analysis. Gen Hosp Psychiatry. 2024.
11. Roberts E, et al. The role of homocysteine, folate, and B12 in depression. J Psychopharmacol.
12. Almeida OP, et al. B-vitamins and depression: clinical trial evidence. Am J Geriatr Psychiatry.
13. Bottiglieri T. Folate, vitamin B12, and S-adenosylmethionine. Psychiatr Clin North Am. 2013.
14. Sarris J, Ravindran A, Yatham LN, et al. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: WFSBP and CANMAT Taskforce. World J Biol Psychiatry. 2022.
15. Wan L, et al. MTHFR C677T polymorphism and depression risk: a meta-analysis. 2018.
16. Shelton RC, et al. Inflammation, BMI, and response to adjunctive L-methylfolate (post-hoc). J Clin Psychiatry.